INBS — Intelligent Bio Solutions Share Price
Last trade - 00:00- $4.77m
- -$4.24m
- $1.26m
- 33
- 55
- 39
- 38
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.51 | ||
| Price to Tang. Book | 0.87 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.01 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -89.77% | ||
| Return on Equity | -116.92% | ||
| Operating Margin | -359.87% | ||
Financial Summary
| Year End 30th Jun | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0 | 0.19 | 1.98 | 0.44 | 1.26 | 4.18 | 11.62 | 367.97% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Intelligent Bio Solutions Inc. is a life sciences company. The Company is engaged in developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. It operates through two segments, namely Commercially available Intelligent Fingerprinting Products (IFPG) and Development Stage Saliva Glucose Biosensor Platform (SGBP). Its product portfolio includes a portable drug screening system that works by analyzing fingerprint sweat using a one-time cartridge and portable handheld reader and also includes a development stage range of biosensor- based Point of Care diagnostic tests (POCT) that are developed in the modalities of clinical chemistry, immunology, tumor markers, allergens, and endocrinology. Its product candidate is the Saliva Glucose Biosensor (SGB), a POCT expected to substitute the finger pricking invasive blood glucose monitoring for diabetic patients. Its Biosensor Platform helps to detect multiple biological analytes.
Directors
- Stephen Boyages NEC (63)
- Harry Simeonidis PRE (53)
- Spiro Sakiris CFO (59)
- Lawrence Fisher IND (82)
- Jonathan Hurd IND (51)
- Leon Kempler IND (68)
- George Margelis IND (60)
- Tom Parmakellis IND (54)
- Jonathan Sessler IND (65)
- Christopher Towers IND (35)
- Last Annual
- June 30th, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- December 5th, 2016
- Public Since
- December 23rd, 2020
- No. of Shareholders
- 495
- No. of Employees
- 17
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 3,117,049
- Address
- 142 West 57Th St Fl11, NEW YORK, 10019
- Web
- https://ibs.inc/
- Phone
- +1 6462336971
- Contact
- Valter Pinto
- Auditors
- BDO Audit Pty Ltd
Upcoming Events for INBS
Similar to INBS
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
As of Today at 21:21 UTC, shares in Intelligent Bio Solutions are trading at $1.82. This share price information is delayed by 15 minutes.
Shares in Intelligent Bio Solutions last closed at $1.82 and the price had moved by -35% over the past 365 days. In terms of relative price strength the Intelligent Bio Solutions share price has underperformed the S&P500 Index by -48.28% over the past year.
The overall consensus recommendation for Intelligent Bio Solutions is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Intelligent Bio Solutions does not currently pay a dividend.
Intelligent Bio Solutions does not currently pay a dividend.
Intelligent Bio Solutions does not currently pay a dividend.
To buy shares in Intelligent Bio Solutions you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $1.82, shares in Intelligent Bio Solutions had a market capitalisation of $5.67m.
Here are the trading details for Intelligent Bio Solutions:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: INBS
Based on an overall assessment of its quality, value and momentum Intelligent Bio Solutions is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Intelligent Bio Solutions is $12.00. That is 559.34% above the last closing price of $1.82.
Analysts covering Intelligent Bio Solutions currently have a consensus Earnings Per Share (EPS) forecast of -$3.67 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Intelligent Bio Solutions. Over the past six months, its share price has outperformed the S&P500 Index by +374.98%.
As of the last closing price of $1.82, shares in Intelligent Bio Solutions were trading -7.37% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Intelligent Bio Solutions PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.82.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Intelligent Bio Solutions' management team is headed by:
- Stephen Boyages - NEC
- Harry Simeonidis - PRE
- Spiro Sakiris - CFO
- Lawrence Fisher - IND
- Jonathan Hurd - IND
- Leon Kempler - IND
- George Margelis - IND
- Tom Parmakellis - IND
- Jonathan Sessler - IND
- Christopher Towers - IND